The Fund's objective is to produce a high and rising income.
Name | % Net Assets |
---|---|
Total | 4.7% |
Sanofi-Aventis | 4.0% |
ENI | 3.9% |
Roche | 3.6% |
OPAP | 3.5% |
Vivendi Universal | 3.5% |
Nestlé | 3.2% |
Telefonica | 3.0% |
Nokia | 2.9% |
Novartis | 2.7% |
Key | % Net Assets |
---|---|
Total | 4.7% |
Sanofi-Aventis | 4.0% |
ENI | 3.9% |
Roche | 3.6% |
Other | 83.8% |
Date | 08-Nov-2022 |
---|---|
NAV | 49.79p |
Currency | GBP |
Change | -0.39p |
% | -0.78% |
YTD change | 49.79p |
YTD % | n/a |
Fund Inception | 08/05/2007 |
---|---|
Fund Manager | Malcolm Millar |
TER | 1.81 (31-Oct-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £100 |
Charges | |
---|---|
Initial | 5.25% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research